You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesloratadine
Accession NumberDB00967  (APRD00324)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDesloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
Structure
Thumb
Synonyms
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
Descarboethoxyloratadine
DESLORATADINE
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClarinexTablet, film coated5 mg/1OralMerck Sharp & Dohme Corp.2001-12-21Not applicableUs
ClarinexSolution.5 mg/mLOralMerck Sharp & Dohme Corp.2004-09-01Not applicableUs
ClarinexTablet, film coated5 mg/1OralA S Medication Solutions2001-12-21Not applicableUs
ClarinexTablet, film coated5 mg/1OralRebel Distributors Corp2002-02-08Not applicableUs
ClarinexTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2002-06-03Not applicableUs
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme Ltd  2001-01-15Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DesloratadineSolution.5 mg/mLOralTaro Pharmaceuticals U.S.A., Inc.2015-07-01Not applicableUs
DesloratadineTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2012-07-02Not applicableUs
DesloratadineTablet5 mg/1OralVirtus Pharmaceuticals2012-07-01Not applicableUs
DesloratadineTablet, film coated5 mg/1OralSun Pharmaceutical Industries Limited2010-11-24Not applicableUs
DesloratadineTablet5 mg/1OralAv Kare, Inc.2015-11-24Not applicableUs
DesloratadineTablet, orally disintegrating5 mg/1OralDr. Reddy's Laboratories Limited2013-01-11Not applicableUs
DesloratadineTablet, film coated5 mg/1OralPaddock Laboratories, LLC2014-01-10Not applicableUs
DesloratadineTablet5 mg/1Oralbryant ranch prepack2012-07-01Not applicableUs
DesloratadineTablet5 mg/1OralAv Pak2015-11-25Not applicableUs
DesloratadineTablet, orally disintegrating2.5 mg/1OralDr. Reddy's Laboratories Limited2013-01-11Not applicableUs
DesloratadineTablet5 mg/1OralSandoz Inc2013-07-01Not applicableUs
DesloratadineTablet, film coated5 mg/1OralLupin Pharmaceuticals, Inc.2013-02-14Not applicableUs
DesloratadineTablet5 mg/1OralAv Pak2013-10-092016-10-13Us
DesloratadineTablet5 mg/1OralBelcher Pharmaceuticals,LLC2012-05-15Not applicableUs
DesloratadineTablet5 mg/1OralAv Kare, Inc.2012-07-05Not applicableUs
DesloratadineTablet5 mg/1OralVirtus Pharmaceuticals2015-06-12Not applicableUs
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine ActavisTablet, film coated5 mgOralActavis Group Ptc Ehf2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Desloratadine RatiopharmTablet, film coated5 mgOralRatiopharm Gmb H2012-01-13Not applicableEu
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AeriusTablet5 mgOralBayer Inc Consumer Care2002-01-10Not applicableCanada
AeriusSyrup0.5 mgOralBayer Inc Consumer CareNot applicableNot applicableCanada
Aerius KidsSyrup0.5 mgOralBayer Inc Consumer Care2005-03-21Not applicableCanada
Allergy Control DesloratadineTablet5 mgOralPharmascience IncNot applicableNot applicableCanada
Allernix Multi SymptomTablet5 mgOralTeva Canada Limited2012-01-31Not applicableCanada
Desloratadine Allergy ControlTablet5 mgOralPharmascience Inc2009-12-24Not applicableCanada
Desloratadine Allergy ControlTablet5 mgOralPharmel Inc2014-03-10Not applicableCanada
Desloratadine TabletsTablet5 mgOralApotex Inc2010-05-27Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
ClaramaxNot Available
NeoClaritynNot Available
Brand mixtures
NameLabellerIngredients
Aerius Dual Action 12 HourBayer Inc Consumer Care
Aerius Dual Action 24 HourBayer Inc Consumer Care
Clarinex-D 12 HourMerck Sharp & Dohme Corp.
SaltsNot Available
Categories
UNIIFVF865388R
CAS number100643-71-8
WeightAverage: 310.821
Monoisotopic: 310.123676325
Chemical FormulaC19H19ClN2
InChI KeyJAUOIFJMECXRGI-UHFFFAOYSA-N
InChI
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
IUPAC Name
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3(8),4,6,12,14-hexaene
SMILES
ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1
Pharmacology
IndicationFor the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
Structured Indications
PharmacodynamicsDesloratadine is a long-acting second-generation H1-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.
Mechanism of actionLike other H1-blockers, Desloratadine competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding82-87%
MetabolismNot Available
Route of eliminationDesloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces.
Half life50 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Desloratadine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desloratadine.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Desloratadine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Desloratadine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desloratadine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Desloratadine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Desloratadine.Approved, Vet Approved
AclidiniumAclidinium may increase the anticholinergic activities of Desloratadine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Desloratadine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Desloratadine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desloratadine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Desloratadine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desloratadine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desloratadine.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Desloratadine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desloratadine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desloratadine.Approved, Illicit, Investigational
AmbenoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Desloratadine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desloratadine.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Desloratadine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desloratadine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desloratadine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Desloratadine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Desloratadine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Desloratadine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Desloratadine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desloratadine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desloratadine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Desloratadine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Desloratadine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desloratadine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Desloratadine.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Desloratadine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Desloratadine.Vet Approved
AzelastineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desloratadine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Desloratadine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Desloratadine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desloratadine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desloratadine.Approved
Benzylpenicilloyl PolylysineDesloratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Desloratadine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Desloratadine.Approved, Vet Approved
BezitramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Desloratadine.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Desloratadine.Approved
Botulinum Toxin Type ADesloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDesloratadine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Desloratadine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Desloratadine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desloratadine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desloratadine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desloratadine.Approved, Investigational
BuprenorphineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desloratadine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desloratadine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desloratadine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desloratadine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desloratadine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Desloratadine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Desloratadine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Desloratadine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Desloratadine.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Desloratadine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desloratadine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Desloratadine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Desloratadine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Desloratadine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Desloratadine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desloratadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desloratadine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desloratadine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desloratadine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desloratadine.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenoxamine.Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative activities of Desloratadine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Desloratadine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desloratadine.Approved, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Desloratadine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desloratadine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Desloratadine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Desloratadine.Approved
CimetropiumDesloratadine may increase the anticholinergic activities of Cimetropium.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desloratadine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Desloratadine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Desloratadine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Desloratadine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Desloratadine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Desloratadine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desloratadine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Desloratadine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desloratadine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Desloratadine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Desloratadine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Desloratadine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desloratadine.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Desloratadine.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Desloratadine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desloratadine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Desloratadine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Desloratadine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Desloratadine.Approved
CoumaphosThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Desloratadine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclopentolate.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Desloratadine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desloratadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Desloratadine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Desloratadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Desloratadine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine.Approved, Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Desloratadine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Desloratadine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Desloratadine.Approved
DecamethoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Demecarium.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Desloratadine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desloratadine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Desloratadine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Desloratadine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desloratadine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desloratadine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desloratadine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Desloratadine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Desloratadine.Approved, Illicit, Vet Approved
DichlorvosThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Desloratadine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desloratadine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Desloratadine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Desloratadine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desloratadine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desloratadine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desloratadine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Desloratadine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Desloratadine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desloratadine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desloratadine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Desloratadine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Desloratadine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Desloratadine.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desloratadine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Desloratadine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Desloratadine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desloratadine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desloratadine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Desloratadine.Experimental
EchothiophateThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Desloratadine.Approved
EdrophoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desloratadine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Desloratadine.Approved, Investigational
EluxadolineDesloratadine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desloratadine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desloratadine.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Desloratadine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Desloratadine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Desloratadine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desloratadine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Desloratadine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Desloratadine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Desloratadine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desloratadine.Approved
EthanolDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desloratadine.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Desloratadine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desloratadine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desloratadine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desloratadine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desloratadine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desloratadine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desloratadine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Desloratadine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Desloratadine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Desloratadine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Desloratadine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desloratadine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desloratadine.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Desloratadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Desloratadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desloratadine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desloratadine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desloratadine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desloratadine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Desloratadine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Desloratadine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desloratadine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desloratadine.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Desloratadine is combined with gabapentin enacarbil.Approved
GalantamineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Desloratadine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desloratadine.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Desloratadine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Desloratadine.Approved
GepironeThe risk or severity of adverse effects can be increased when Desloratadine is combined with Gepirone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desloratadine.Approved, Illicit
GlycopyrroniumDesloratadine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Desloratadine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Desloratadine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desloratadine.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Desloratadine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desloratadine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Desloratadine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desloratadine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desloratadine.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Desloratadine.Approved, Vet Approved
HydrocodoneDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Desloratadine.Approved, Vet Approved
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Desloratadine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desloratadine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Desloratadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Desloratadine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Desloratadine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Desloratadine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Desloratadine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Desloratadine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Desloratadine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Desloratadine.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Desloratadine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Desloratadine.Approved, Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Desloratadine.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desloratadine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Desloratadine.Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Desloratadine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desloratadine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Desloratadine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desloratadine.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Desloratadine.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Desloratadine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Desloratadine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Desloratadine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Desloratadine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Desloratadine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Desloratadine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Desloratadine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desloratadine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Desloratadine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desloratadine.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Desloratadine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desloratadine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desloratadine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Desloratadine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Desloratadine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Desloratadine.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Desloratadine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desloratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desloratadine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Desloratadine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desloratadine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Desloratadine.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Vet Approved
MalathionThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Malathion.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Desloratadine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desloratadine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Desloratadine.Vet Approved
MefloquineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desloratadine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Desloratadine.Approved
MemantineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Memantine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Desloratadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Desloratadine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desloratadine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desloratadine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desloratadine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desloratadine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Desloratadine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desloratadine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desloratadine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desloratadine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Desloratadine.Approved
MethotrimeprazineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desloratadine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desloratadine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Desloratadine.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Desloratadine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desloratadine.Approved, Investigational
MetyrosineDesloratadine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Desloratadine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Desloratadine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Desloratadine is combined with Milnacipran.Approved
MinaprineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mirabegron.Approved
MirtazapineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Desloratadine.Approved, Investigational
MMDAMMDA may decrease the sedative activities of Desloratadine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Desloratadine.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Desloratadine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desloratadine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Desloratadine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Desloratadine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desloratadine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Desloratadine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Desloratadine.Approved, Vet Approved
NefazodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Desloratadine.Approved
NeostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Desloratadine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Desloratadine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Desloratadine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Desloratadine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desloratadine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desloratadine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Desloratadine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Desloratadine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desloratadine.Approved
NVA237The risk or severity of adverse effects can be increased when Desloratadine is combined with NVA237.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Desloratadine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desloratadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Desloratadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desloratadine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Desloratadine.Approved, Illicit
OrphenadrineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Desloratadine.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Desloratadine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desloratadine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desloratadine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desloratadine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desloratadine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desloratadine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Desloratadine.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Desloratadine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desloratadine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Desloratadine.Approved, Investigational
ParaldehydeDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Desloratadine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desloratadine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desloratadine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Desloratadine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desloratadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desloratadine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Desloratadine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desloratadine.Approved
PhenterminePhentermine may decrease the sedative activities of Desloratadine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Desloratadine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine.Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Desloratadine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desloratadine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Desloratadine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pizotifen.Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Desloratadine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Desloratadine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Desloratadine.Approved
Potassium ChlorideDesloratadine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleDesloratadine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Desloratadine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desloratadine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Desloratadine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desloratadine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Desloratadine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Desloratadine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Desloratadine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desloratadine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desloratadine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Desloratadine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desloratadine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Desloratadine.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Desloratadine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Desloratadine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desloratadine.Approved, Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desloratadine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Desloratadine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Desloratadine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desloratadine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Desloratadine.Approved
PyridostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Pyridostigmine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desloratadine.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Desloratadine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Desloratadine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Desloratadine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Desloratadine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon.Approved, Investigational
RamosetronDesloratadine may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Desloratadine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Desloratadine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desloratadine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desloratadine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Desloratadine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Desloratadine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Desloratadine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Desloratadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Desloratadine.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Desloratadine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Desloratadine.Approved
RivastigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Desloratadine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Desloratadine.Vet Approved
RopiniroleDesloratadine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desloratadine.Approved
RotigotineDesloratadine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desloratadine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desloratadine.Experimental
Sage 547The risk or severity of adverse effects can be increased when Desloratadine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Desloratadine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Desloratadine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Scopolamine butylbromide.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desloratadine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Desloratadine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Desloratadine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desloratadine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Desloratadine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Desloratadine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Desloratadine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Desloratadine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Solifenacin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Desloratadine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Desloratadine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Desloratadine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desloratadine.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desloratadine.Approved
SuvorexantDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Desloratadine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Desloratadine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Desloratadine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Desloratadine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Desloratadine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desloratadine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Desloratadine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desloratadine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desloratadine.Investigational
ThalidomideDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desloratadine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desloratadine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Desloratadine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desloratadine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Desloratadine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desloratadine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Desloratadine.Approved
TiotropiumDesloratadine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desloratadine.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tolterodine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Desloratadine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Desloratadine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Desloratadine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desloratadine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desloratadine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desloratadine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Desloratadine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Desloratadine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desloratadine.Approved
TrichlorfonThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Desloratadine.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desloratadine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Desloratadine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trimethaphan.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desloratadine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desloratadine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Desloratadine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Desloratadine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tubocurarine.Approved
Uc1010The risk or severity of adverse effects can be increased when Desloratadine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Desloratadine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Desloratadine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desloratadine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Desloratadine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Desloratadine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Desloratadine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Desloratadine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Desloratadine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Desloratadine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Desloratadine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Desloratadine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Desloratadine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desloratadine.Vet Approved
ZolpidemDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desloratadine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Desloratadine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desloratadine.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Zoltan Toth, “Processes for preparation of polymorphic forms of desloratadine.” U.S. Patent US20040242619, issued December 02, 2004.

US20040242619
General References
  1. Mann RD, Pearce GL, Dunn N, Shakir S: Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000 Apr 29;320(7243):1184-6. [PubMed:10784544 ]
  2. Glass DJ, Harper AS: Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract. 2003 Aug 13;4:10. Epub 2003 Aug 13. [PubMed:12917016 ]
  3. See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. [PubMed:14655812 ]
  4. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052 ]
  5. Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. [PubMed:19539095 ]
  6. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. [PubMed:17902729 ]
  7. Bachert C, Maurer M: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000. [PubMed:20067329 ]
  8. Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. [PubMed:12642846 ]
External Links
ATC CodesR06AX27
AHFS Codes
  • 04:08.00
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.965
Caco-2 permeable-0.5121
P-glycoprotein substrateSubstrate0.7758
P-glycoprotein inhibitor IInhibitor0.6694
P-glycoprotein inhibitor IINon-inhibitor0.794
Renal organic cation transporterInhibitor0.6979
CYP450 2C9 substrateNon-substrate0.8554
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5634
CYP450 1A2 substrateInhibitor0.7786
CYP450 2C9 inhibitorNon-inhibitor0.738
CYP450 2D6 inhibitorNon-inhibitor0.7377
CYP450 2C19 inhibitorNon-inhibitor0.7837
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.6514
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0370 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7382
hERG inhibition (predictor II)Inhibitor0.8016
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp
  • Doctor reddys laboratories ltd
  • Schering plough corp
  • Orchid healthcare
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
Tablet, multilayer, extended releaseOral
SyrupOral0.5 mg
SolutionOral.5 mg/mL
Tablet, film coatedOral5 mg/1
Tablet, extended releaseOral
Tablet, film coatedOral5 mg
TabletOral5 mg/1
Tablet, orally disintegratingOral2.5 mg/1
Tablet, orally disintegratingOral5 mg/1
SolutionOral0.5 mg/ml
Tablet, orally disintegratingOral2.5 mg
Tablet, orally disintegratingOral5 mg
Prices
Unit descriptionCostUnit
Clarinex Reditabs 30 5 mg Dispersible Tablet Box150.0USD box
Clarinex Reditabs 30 2.5 mg Dispersible Tablet Box147.14USD box
Clarinex-D 24 Hour 5-240 mg 24 Hour tablet5.0USD tablet
Clarinex-d 24 hour tablet4.8USD tablet
Clarinex 5 mg tablet4.57USD tablet
Clarinex-D 12 Hour 2.5-120 mg 12 Hour tablet3.2USD tablet
Clarinex-d 12 hour tablet3.08USD tablet
Clarinex 0.5 mg/ml Syrup0.48USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2267136 No2000-11-282018-02-06Canada
CA2294352 No2008-05-062018-07-01Canada
US5178878 No1993-01-122010-01-12Us
US5607697 Yes1995-12-072015-12-07Us
US6100274 Yes2000-01-072020-01-07Us
US6514520 Yes1998-12-012018-12-01Us
US6709676 No2001-02-182021-02-18Us
US6979463 No2002-03-282022-03-28Us
US7405223 Yes2000-01-072020-01-07Us
US7618649 Yes2001-06-192021-06-19Us
US7820199 Yes2002-09-282022-09-28Us
US8187630 No2000-12-192020-12-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00395 mg/mLALOGPS
logP3.48ALOGPS
logP3.97ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.92 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity101.04 m3·mol-1ChemAxon
Polarizability34.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzocycloheptapyridines. These are aromatic compounds containing a benzene ring and a pyridine ring fused to a seven membered carbocycle.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzocycloheptapyridines
Sub ClassNot Available
Direct ParentBenzocycloheptapyridines
Alternative Parents
Substituents
  • Benzocycloheptapyridine
  • Chlorobenzene
  • Benzenoid
  • Pyridine
  • Piperidine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr: Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol. 2004 Dec;135(4):313-8. Epub 2004 Nov 24. [PubMed:15564772 ]
  2. Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5. [PubMed:7581058 ]
  3. Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27. [PubMed:8174605 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052 ]
  6. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. [PubMed:17902729 ]
  7. Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. [PubMed:12642846 ]
  8. Dhanya NB, Thasleem Z, Rai R, Srinivas CR: Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):361-3. [PubMed:18797058 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 03:58